| Unadjusted | Partially adjustedc | Partially adjustedc | Fully adjustedc | Gender-specific (fully adjustedc) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | ||||||||||
 |  |  |  | Men | Women |  | ||||||||
uOR | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | Waldb | ||
Functional impairment | ||||||||||||||
 Genderb | Women | 1.09 | (0.81–1.48) | 1.11 | (0.73–1.69) |  |  | 0.93 | (0.59–1.48) | NA |  | NA |  |  |
 HSCL-Anxietyb | Yes | 6.24*** | (4.48–8.70) | 2.79*** | (1.75–4.46) |  |  | 2.25** | (1.31–3.87) | 3.23*** | (1.71–6.10) | 1.21 | (0.56–2.61) | 0.027 |
 HSCL-Depb | Yes | 5.70*** | (4.15–7.85) | 1.94** | (1.19–3.16) |  |  | 1.25 | (0.72–2.20) | 1.83 | (0.95–3.52) | 0.66 | (0.30–1.46) | 0.024 |
 HTQ-PTSDb | Yes | 6.22*** | (4.42–8.76) | 2.54*** | (1.56–4.13) |  |  | 2.12** | (1.21–3.71) | 3.12*** | (1.62–6.02) | 1.12 | (0.51–2.43) | 0.023 |
 Chronic painb | Moderate | 3.88** | (1.62–9.3) |  |  | 3.22* | (1.32–7.9) | 2.50 | (1.00–6.27) | 2.50 | (1.00–6.27) | 2.50 | (1.00–6.27) | 0.385 |
Severe | 44.1*** | (19.6–99.0) |  |  | 35.6*** | (15.5–81.5) | 20.3*** | (8.56–48.0) | 20.3*** | (8.56–48.0) | 20.3c | (8.56–48.0) | 0.704 |